PepBank has 4 palmitoyl tripeptide-1 studies with results. 2 of them gave palmitoyl tripeptide-1, with 3 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 3 results and 7 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Palmitoyl tripeptide-1 is N-palmitoyl-GHK, also called pal-GHK. It differs from free GHK and GHK-Cu. Matrixyl 3000 is a blend that contains pal-GHK and palmitoyl tetrapeptide-7.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
3 amino acids · 1 modification
Calculated from the two sequences. Curated notes are shown as given.
3 of 3 aligned residues identical (100%) · 1 modified residue · GHK 1–3
Differences from the parent
Basis: N-terminal palmitoylation distinguishes pal-GHK from GHK.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
A modification changes this value and is not modeled here (for example a lipid, metal or linker).
3 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 10231864(opens in a new tab)
CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)OPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
4 of 7 studies have results (57%), published 2026. Top row: every study. Bottom row: studies with results about Palmitoyl tripeptide-1, by class. The rows use different scales.
Studies7 in all, 2009 to 2026
Studies with results4 in all, 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
1 more mentions it but does not test it. They are not trials of Palmitoyl tripeptide-1: they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
7 studies match. Retracted studies are left out.
Showing 5 of 7 studiesquery qry_1bf09fa5150e6154a90e6b74
4 studies
In vitro (cells) · 2026
Wang et al. 2026Journal of cosmetic dermatologycited by 1
PMID 41527525PMC12797011DOI 10.1111/jocd.70638PUB-41527525
Not a test of Palmitoyl tripeptide-1 alone · 2026
Zheng et al. 2026European journal of pharmacology
PMID 42575238DOI 10.1016/j.ejphar.2026.179217PUB-42575238
In vitro (cells) · 2026
Zang et al. 2026International journal of cosmetic science
PMID 42683869DOI 10.1111/ics.70140PUB-42683869
Not a test of Palmitoyl tripeptide-1 alone · 2026
Trzaska et al. 2026International journal of pharmaceutics
PMID 42790608DOI 10.1016/j.ijpharm.2026.127447PUB-42790608
1 study
PubMed tag: none · 2009
Chirita et al. 2009Analytica chimica actacited by 10
PMID 19393372DOI 10.1016/j.aca.2009.03.015PUB-19393372
These studies name Palmitoyl tripeptide-1 but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: review-article, Review · 2025
Mortazavi et al. 2025BioImpacts : BIcited by 3
PMID 39963574PMC11830136DOI 10.34172/bi.30071PUB-39963574
PubMed tag: none · 2025
Hong et al. 2025Biochemical and biophysical research communicationscited by 2
PMID 39632290DOI 10.1016/j.bbrc.2024.151060PUB-39632290
Page 1 of 1
Wang C · Journal of cosmetic dermatology · 2026
In vitro (cells) · 5 results
Zang S · International journal of cosmetic science · 2026
In vitro (cells) · 18 results
Zheng X · European journal of pharmacology · 2026
Not a test of Palmitoyl tripeptide-1 alone · 8 results
Trzaska AH · International journal of pharmaceutics · 2026
Not a test of Palmitoyl tripeptide-1 alone · 6 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | No matching approved drug record returned from the reviewed openFDA active-ingredient queries. The FDA UNII entry establishes identity, not approval. Cosmetic use does not establish drug approval. | 27 Oct 2026 | precision.fda.gov (opens in a new tab) |
| EU | EMA | No medicinal authorisation was established from the reviewed sources. The unresolved cosmetic inventory entry does not establish medicinal approval. | 27 Oct 2026 | Not recorded |
| Sport | WADA | Status unknown The 2026 list does not name palmitoyl tripeptide-1. | 2026 List | wada-ama.org (opens in a new tab) |
| European Union | Note | SpecialChem lists the INCI ingredient and reports CosIng reference 56919. The existing reference 92513 was not confirmed. Both official detail pages failed to return usable records. No medicinal approval was established. | 27 Oct 2026 | specialchem.com (opens in a new tab) |
| Canada | Note | Health Canada NHPID lists palmitoyl tripeptide-1 as a non-medicinal skin-conditioning ingredient for topical use only. Approved Chemical Name is an identity category, not approval of a medicine. | 27 Oct 2026 | webprod.hc-sc.gc.ca (opens in a new tab) |
1 safety result for Palmitoyl tripeptide-1.
No safety results from studies in people
In human dermal fibroblasts, palmitoyl tripeptide-1 produced no detectable cytotoxicity following UV exposure.
In vitro (cells)human
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Palmitoyl tripeptide-1: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 2 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Skin and hairSkin and wound | No results | No results | Lab: 2 results from 2 studies: 2 increase. Strongest design: In vitro (cells) | No results | 2 |
| Adverse eventsSkin and wound | No results | No results | Lab: 1 result from 1 study: 1 no significant change. Strongest design: In vitro (cells) | No results | 1 |
2 outcome groups shown of 2 · 3 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.